Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series.
J Allergy Clin Immunol Glob
; 2(2): 100096, 2023 May.
Article
em En
| MEDLINE
| ID: mdl-37780793
This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis. In every case, dupilumab facial redness subsided without discontinuation of dupilumab within 3 months after onset.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Allergy Clin Immunol Glob
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Japão